Practice changing | A four-month rifapentine regiment with moxifloxacin is noninferior to the standard 6-month regimen in the treatment of tuberculosis.
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis – New England Journal of Medicine Commentary: Four-month TB treatment matches six-month standard of care – Aidsmap
The post Practice changing | A four-month rifapentine regiment with moxifloxacin is noninferior to the standard 6-month regimen in the treatment of tuberculosis. appeared first on Links Medicus.
[Press release – not published yet] Moderna announces positive initial booster data against SARS-CoV-2 variants of concern.
Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern – Moderna Commentary: We just got our first evidence that Moderna’s coronavirus booster shot works to fight variants – Insider Commentaries on Twitter Moderna announces that a single dose of their #COVID19 booster shot provides a strong immunologic response to the variant first […]
The post [Press release – not published yet] Moderna announces positive initial booster data against SARS-CoV-2 variants of concern. appeared first on Links Medicus.
Cohort study shows inadequate antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients.
Antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients – Prospective cohort study – Clinical Microbiology and Infection Commentary on Twitter The studies of mRNA vax in people with transplants are getting bigger: still the same message. Some protection, but not enough. This time, 308 people with kidney transplants in Israel, BNT-Pfizer vaccine […]
The post Cohort study shows inadequate antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients. appeared first on Links Medicus.
Organ transplant recipients remain vulnerable to Covid-19 even after second vaccine dose.
Organ Transplant Recipients Remain Vulnerable to Covid-19 Even After Second Vaccine Dose – Johns Hopkins Medicine Original Study: Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients – JAMA
The post Organ transplant recipients remain vulnerable to Covid-19 even after second vaccine dose. appeared first on Links Medicus.
Observational study in Israel: Pfizer-BioNTech is 95.3% effective against SARS-CoV-2 infection.
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data – The Lancet Commentaries: Expert reaction to Israel nation-wide study looking at Pfizer vaccine effectiveness – Science Media Centre AND Covid-19: Two doses of Pfizer […]
The post Observational study in Israel: Pfizer-BioNTech is 95.3% effective against SARS-CoV-2 infection. appeared first on Links Medicus.
Observational study in Qatar: Pfizer–BioNTech Covid vaccine is 89.5% effective against B.1.1.7 variant and 75.0% effective against B.1.351 variant. Vaccine effectiveness against severe, critical, or fatal disease with any SARS-CoV-2 variant was very high,
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants – New England Journal of Medicine Commentary: Pfizer-BioNTech vaccine offers strong protection against key variants of concern, real-world data from Qatar shows – The Washington Post Commentary on Twitter ?GET BOTH DOSES! Great variants & #COVID19 vaccine news—Pfizer/BioNTech vaccine had great efficacy […]
The post Observational study in Qatar: Pfizer–BioNTech Covid vaccine is 89.5% effective against B.1.1.7 variant and 75.0% effective against B.1.351 variant. Vaccine effectiveness against severe, critical, or fatal disease with any SARS-CoV-2 variant was very high, at 97.4%. appeared first on Links Medicus.
RCT: Novavax vaccine is 49.4% effective against B.1.351 SARS-CoV-2 variant.
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant – New England Journal of Medicine
The post RCT: Novavax vaccine is 49.4% effective against B.1.351 SARS-CoV-2 variant. appeared first on Links Medicus.
In shock move, US backs waiving patents on COVID vaccines. “The development from the Biden administration draws cheers from public health researchers and ire from drugmakers.”
In shock move, US backs waiving patents on COVID vaccines – Nature See also: U.S. will back proposal to waive intellectual property rights and boost Covid-19 vaccine production – STAT AND Statement from the Executive Director of UNAIDS, Winnie Byanyima on the decision by the United States of America to support the TRIPS waiver for […]
The post In shock move, US backs waiving patents on COVID vaccines. “The development from the Biden administration draws cheers from public health researchers and ire from drugmakers.” appeared first on Links Medicus.
ATS Guideline: Nucleic acid–based testing for noninfluenza viral pathogens in adults with suspected community-acquired pneumonia – Testing should be considered only in patients with severe CAP and in immunocompromised patients
Nucleic Acid–based Testing for Noninfluenza Viral Pathogens in Adults with Suspected Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice Guideline News Release: New clinical practice guideline on community acquired pneumonia – American Thoracic Society
The post ATS Guideline: Nucleic acid–based testing for noninfluenza viral pathogens in adults with suspected community-acquired pneumonia – Testing should be considered only in patients with severe CAP and in immunocompromised patients appeared first on Links Medicus.
Perspective | We may never achieve long-term global herd immunity for COVID. But if we’re all vaccinated, we’ll be safe from the worst
We may never achieve long-term global herd immunity for COVID. But if we’re all vaccinated, we’ll be safe from the worst – The Conversation See also: Reaching ‘Herd Immunity’ Is Unlikely in the U.S., Experts Now Believe – The New York Times (free registration required) AND We May Never Get to Herd Immunity – Think Global Health
The post Perspective | We may never achieve long-term global herd immunity for COVID. But if we’re all vaccinated, we’ll be safe from the worst appeared first on Links Medicus.